Search Results - Seth Toback
- Showing 1 - 5 results of 5
-
1
Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines by Anthony M. Marchese, Raj Kalkeri, Muruga Vadivale, Nungruthai Suntronwong, Seth Toback, Yong Poovorawan
Published in Expert Review of Vaccines (2023-12-01)Get full text
Article -
2
Development of a novel observer-reported outcome measure for the assessment of Respiratory Syncytial Virus (RSV) infection symptoms in pediatric clinical trials by Sandy Lewis, Carla DeMuro, Stan L. Block, Shelly Senders, Paul Wisman, Seth Toback, Jason W. Chien, Valerie Williams
Published in Journal of Patient-Reported Outcomes (2018-02-01)Get full text
Article -
3
Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines by Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, Dawn Odom, Anthony M. Marchese, Mitra Montazeri, Shardul Odak, Laurin Jackson, Hadi Beyhaghi, Seth Toback
Published in Vaccines (2024-07-01)Get full text
Article -
4
Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study by Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, Dawn Odom, Anthony M. Marchese, Mitra Montazeri, Shardul Odak, Laurin Jackson, Angela Miller, Seth Toback
Published in Vaccines (2024-01-01)Get full text
Article -
5
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine by Eddie Underwood, Lisa M. Dunkle, Shabir A. Madhi, Cynthia L. Gay, Paul T. Heath, Karen L. Kotloff, Katherine Smith, Gordon Chau, Shirley Galbiati, Alice McGarry, Wayne Woo, Iksung Cho, Katia Alves, Germán Áñez, Chijioke Bennett, Vivek Shinde, Louis Fries, Raburn M. Mallory, Gregory M. Glenn, Seth Toback
Published in Expert Review of Vaccines (2023-12-01)Get full text
Article